[go: up one dir, main page]

DE60036537D1 - Zusammensetzungen zur gentherapie von diabetes - Google Patents

Zusammensetzungen zur gentherapie von diabetes

Info

Publication number
DE60036537D1
DE60036537D1 DE60036537T DE60036537T DE60036537D1 DE 60036537 D1 DE60036537 D1 DE 60036537D1 DE 60036537 T DE60036537 T DE 60036537T DE 60036537 T DE60036537 T DE 60036537T DE 60036537 D1 DE60036537 D1 DE 60036537D1
Authority
DE
Germany
Prior art keywords
compositions
diabetes
expressed
genetherapy
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036537T
Other languages
English (en)
Other versions
DE60036537T2 (de
Inventor
Matthew J During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engene Inc
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Publication of DE60036537D1 publication Critical patent/DE60036537D1/de
Application granted granted Critical
Publication of DE60036537T2 publication Critical patent/DE60036537T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60036537T 1999-02-19 2000-02-22 Zusammensetzungen zur gentherapie von diabetes Expired - Lifetime DE60036537T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12097599P 1999-02-19 1999-02-19
US120975P 1999-02-19
PCT/US2000/040069 WO2000057921A2 (en) 1999-02-19 2000-02-22 Peroral gene therapy of diabetes and obesity

Publications (2)

Publication Number Publication Date
DE60036537D1 true DE60036537D1 (de) 2007-11-08
DE60036537T2 DE60036537T2 (de) 2008-06-19

Family

ID=22393646

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036537T Expired - Lifetime DE60036537T2 (de) 1999-02-19 2000-02-22 Zusammensetzungen zur gentherapie von diabetes

Country Status (8)

Country Link
US (1) US6503887B1 (de)
EP (1) EP1153131B1 (de)
JP (1) JP2002540175A (de)
AT (1) ATE374251T1 (de)
AU (1) AU777988B2 (de)
CA (1) CA2364417C (de)
DE (1) DE60036537T2 (de)
WO (1) WO2000057921A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122349A0 (en) * 1995-06-07 1998-04-05 Univ Yale Adeno-associated viral vectors
AU784499B2 (en) * 2000-03-13 2006-04-13 Engene, Inc. Compositions and methods for regulated protein expression in gut
WO2002050264A2 (en) * 2000-12-18 2002-06-27 Wyeth Promoters and recombinant expression constructs
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
FR2852247A1 (fr) * 2003-03-11 2004-09-17 Centre Nat Rech Scient Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
WO2008020318A2 (en) * 2006-03-30 2008-02-21 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
WO2012047091A1 (en) * 2010-10-08 2012-04-12 Universiti Putra Malaysia Glp-1 promoter mediated insulin expression for the treatment of diabetes
US10696946B2 (en) 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
EP3233131A1 (de) * 2014-12-16 2017-10-25 Board of Regents of the University of Nebraska Gentherapie für juvenile neuronale ceroid-lipofuszinose
EP3371209A1 (de) 2015-11-06 2018-09-12 The Board of Trustees of the University of Illinois Chimäre ox40l-jagged-1-polypeptide und verwendungen davon
AU2017281469B2 (en) 2016-06-22 2023-08-31 David Klatzmann Genetically modified T lymphocytes
EP3565591A1 (de) 2017-01-06 2019-11-13 Stabilitech Biopharma Ltd Virus
US20220226501A1 (en) * 2019-05-31 2022-07-21 Universitat Autònoma De Barcelona Insulin gene therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837693A (en) 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
FR2732978B1 (fr) 1995-04-14 1997-05-30 Inst Nat Sante Rech Med Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
IL122349A0 (en) 1995-06-07 1998-04-05 Univ Yale Adeno-associated viral vectors
US5646034A (en) 1995-06-07 1997-07-08 Mamounas; Michael Increasing rAAV titer
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
EP1005376B1 (de) * 1997-03-14 2010-11-03 The Children's Hospital of Philadelphia Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie

Also Published As

Publication number Publication date
US6503887B1 (en) 2003-01-07
AU3774700A (en) 2000-10-16
WO2000057921A2 (en) 2000-10-05
EP1153131A2 (de) 2001-11-14
CA2364417A1 (en) 2000-10-05
JP2002540175A (ja) 2002-11-26
CA2364417C (en) 2013-11-05
EP1153131B1 (de) 2007-09-26
WO2000057921A3 (en) 2001-01-04
AU777988B2 (en) 2004-11-11
DE60036537T2 (de) 2008-06-19
ATE374251T1 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
AU4981101A (en) Subtilisin variants
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
EP1670450B8 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
WO2001021766A8 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
ATE543873T1 (de) Herstellung von 3-hydroxypropionsäure mittels beta-alanine-pyruvat-aminotrransferase
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
BRPI0519170A2 (pt) formulaÇÕes de hormânio de crescimento humano que compreendem um aminoÁcido nço naturalmente codificado
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
WO2003023000A3 (en) Linear dna fragments for gene expression
WO2004074450A8 (en) Combination therapy for treating protein deficiencies
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
WO2008098169A3 (en) Compositions and methods including expression and bioactivity of bovine follicle stimulating hormone
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
WO2001029175A3 (en) Antisense modulation of fra-1 expression
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста
WO2004071443A3 (en) Methods and compositions for modulating stem cells
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna

Legal Events

Date Code Title Description
8364 No opposition during term of opposition